^
5ms
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
P1, N=74, Active, not recruiting, Tyligand Bioscience (Shanghai) Limited | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
TSN084
6ms
TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=114, Recruiting, Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Dec 2025
Trial completion date • Trial primary completion date • Metastases
|
TSN084
7ms
TSN084 Treating Patients With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=114, Recruiting, Tyligand Bioscience (Shanghai) Limited
New P1 trial • Metastases
|
TSN084
7ms
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
P1, N=74, Recruiting, Tyligand Bioscience (Shanghai) Limited | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
Trial completion date • Trial primary completion date • Metastases
|
TSN084
over2years
Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. (clinicaltrials.gov)
P1, N=74, Recruiting, Tyligand Bioscience (Shanghai) Limited
New P1 trial
|
MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
|
TSN084